Adamax is a name that circulates in the research-peptide trade, not in science. The compound is presented as a derivative of Semax — a Russian nootropic peptide — carrying an added adamantane group, and it is credited with being several times more potent than the original. This article has to be different from the others in this library, because there is not a single scientific paper on Adamax: none in humans, none in animals, none in cells, and not one measurement of pharmacokinetics or toxicity. So we will describe two things honestly — Semax itself, and what attaching adamantane does to a peptide — and then explain why adding those together does not produce knowledge about Adamax. This compound is not part of the SWISS LAB range.
What Adamax is said to be
The claim runs as follows: the heptapeptide Semax with an adamantane cage attached, that cage being a rigid, roughly spherical hydrocarbon familiar from antiviral drugs. The class label “ACTH analogue” was assigned to this compound purely by analogy with Semax, not on the basis of any measurement. No publication states the structure of Adamax — which means there is nothing to compare a commercial description against: it is not known where on the molecule the cage is supposed to sit, through what bond, or whether the substance is even the same from one supplier to the next.
No research at all — what that means precisely
In PubMed the term “Adamax” returns several dozen hits and none concerns a peptide: the name collides with the AdaMax machine-learning algorithm used in neural-network papers, so the results are computer-science articles about image classification or forecasting. Chemistry-targeted queries — “adamantyl semax”, “adamantane semax”, “adamantane ACTH analogue” — return nothing. The ClinicalTrials.gov registry holds no study of this substance. So this is not a “poorly studied” compound, as many research peptides are, where at least rodent work exists. It is unstudied in the strict sense: every sentence one can find about its action comes either from the literature on Semax or from nowhere.
Semax — the original, about which something is known
Semax is a seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro): the 4-7 fragment of adrenocorticotropic hormone with a Pro-Gly-Pro tripeptide attached at the end. Given intranasally to rodents it affects learning and memory formation and has marked neuroprotective effects. A 2006 paper showed that cell membranes from the rat basal forebrain carry specific binding sites for Semax (dissociation constant 2.4 nM), and that intranasal administration at 50 and 250 micrograms per kilogram of body weight raised levels of BDNF — a protein that supports synaptic plasticity — after three hours in the basal forebrain, though not in the cerebellum.
In humans, Semax is in clinical use in Russia. In a 2018 study, 110 patients after ischaemic stroke were split into early (89 plus or minus 9 days after the stroke) and late rehabilitation groups (214 plus or minus 22 days), and within each group a subgroup received Semax in two ten-day courses at a daily amount of 6000 micrograms. Giving the peptide raised plasma BDNF levels and accelerated improvement on the Barthel index. Two caveats belong here, however: the abstract mentions neither randomisation nor placebo, and almost the entire Semax literature comes from Russian centres — a limitation shared across this group of peptides.
Adamantane — what the “cage” really does
Adamantane is a ten-carbon, very rigid and strongly lipophilic (fat-loving) hydrocarbon. Medicinal chemistry calls it the “lipophilic bullet”: it is bolted onto known molecules precisely in order to raise their lipophilicity and stability and thereby improve their pharmacokinetics. Amantadine and rimantadine (antivirals) are built on that skeleton, as are the DPP-4 inhibitors vildagliptin and saxagliptin. An important detail from the same review: in series where adamantane was attached to sulfonylurea derivatives and to anabolic steroids, potency depended less on lipophilicity itself than on the shape and substitution of the cage — adding methyl groups to it markedly lowered activity. In other words, this is not a cosmetic modification whose outcome can be predicted with a pencil.
On peptides it has been tested twice. In a 1997 paper, seven derivatives of an enkephalin analogue were conjugated with adamantane: those carrying the cage at the C-terminus were far more lipophilic than the parent peptide, showed moderate opioid activity in a tissue assay, and four of them produced a clear antinociceptive effect in mice after subcutaneous injection — which the authors attributed to better passage across the blood-brain barrier by a peptide that is otherwise poorly absorbed. In a 1999 paper, attaching an adamantyl group to peptide nucleic acids greatly improved cellular uptake, but the size of that effect depended on the cell line and on the sequence. The lesson from both papers is the same: the adamantane cage genuinely changes what happens to a molecule in the body, but the direction and magnitude of that change cannot be guessed.
Why Semax plus adamantane does not add up to Adamax
The best demonstration is a 2016 paper in which Semax was altered in a genuinely small way: the amino group at its start was blocked (acetylation). The resulting Ac-Semax bound copper in a different geometry than Semax, had a different redox potential, and above all stopped protecting neuroblastoma cells against copper toxicity — the authors identified the free amino terminus as critical for that protection. If adding two carbon atoms and one oxygen was enough to abolish one of the peptide's measured functions, then adding a ten-carbon cage is a change of another order. The claim “two to three times stronger than Semax” therefore has no measurement behind it: to say it, somebody would first have to measure the potency of both molecules in the same model, and no such paper exists.
There is also an argument running the other way. Drugs based on adamantane act through mechanisms entirely unlike those of ACTH peptides — they block ion channels or enzymes. There is no ground for inferring a mild profile for an adamantane derivative from the mild profile of Semax, because the cage changes exactly that: where the molecule goes and how long it stays.
Safety and the limits of the evidence
There is nothing here to qualify, because there is no evidence. Zero cell studies, zero animal studies, zero concentration measurements, zero toxicology — for Adamax itself. Even the original has clinical data coming almost exclusively from one country and from studies with no described randomisation. The absence of a published structure has one further practical consequence, for quality control: a certificate of analysis confirms that the contents of a vial match a declared structure, so when no independent source states that structure, the certificate can only repeat the seller's declaration (we cover this in our piece on how to read a CoA). We deliberately give no methods of use and no doses — all the more so because carrying Semax schedules across is baseless in either direction: adamantylation changes both the distribution and the lifetime of a molecule.
Why it is not part of our range
First reason: zero scientific literature. The SWISS LAB encyclopaedia describes compounds through what has been studied about them; for Adamax not one sentence about its action could be written without concealing that the sentence comes from a paper on a different molecule. Second: with no published reference structure, the identity of the substance cannot be verified independently — a buyer has no way of establishing what is in the vial, and a certificate compares the contents only against a declaration. Third: the reasoning by analogy on which its whole reputation rests is unreliable in this very case — a smaller modification of Semax has already abolished one of its measured functions, and the adamantane cage alters a molecule's fate in ways that depend on details nobody here has described. This is not a judgement of anyone interested in the compound; it is a statement that there is no basis for either a recommendation or a warning about any specific risk.
The wider context — regulatory peptides of the ACTH family
Semax is not alone in this family. Beside it stands Selank — another short regulatory peptide from the same research school — and both share one trait: a literature concentrated in a single country and few placebo-controlled trials. We cover the original itself at greater length in our piece on Semax. Within that family, Adamax is an extreme and instructive case: it shows how readily a trade name takes over the research record of a molecule it merely refers to.
Summary
Adamax is a declaration, not a compound described in science. About its original, Semax, a fair amount is known: it has specific binding sites in the rat brain, it raises BDNF, and it has been studied in patients after stroke — though almost exclusively in one country. About adamantylation a fair amount is known too: it raises lipophilicity, improves brain entry and alters activity in ways that depend on the shape of the cage and its point of attachment. Putting those two bodies of knowledge together does not create a third. The evidence base for Adamax is empty — there is not one paper on the compound, and the activity attributed to it is carried over wholesale from the literature on Semax.
Sources
- Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;118(3. Vyp. 2):61-68. PMID: 29798983. DOI: 10.17116/jnevro20181183261-68. pubmed.ncbi.nlm.nih.gov/29798983
- Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry. 2006;97 Suppl 1:82-86. PMID: 16635254. DOI: 10.1111/j.1471-4159.2006.03658.x. pubmed.ncbi.nlm.nih.gov/16635254
- Magrì A, Tabbì G, Giuffrida A, et al. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. Journal of Inorganic Biochemistry. 2016;164:59-69. PMID: 27586814. DOI: 10.1016/j.jinorgbio.2016.08.013. pubmed.ncbi.nlm.nih.gov/27586814
- Kitagawa K, Mizobuchi N, Hama T, et al. Synthesis and antinociceptive activity of [D-Ala2]Leu-enkephalin derivatives conjugated with the adamantane moiety. Chemical & Pharmaceutical Bulletin. 1997;45(11):1782-1787. PMID: 9396154. DOI: 10.1248/cpb.45.1782. pubmed.ncbi.nlm.nih.gov/9396154
- Ljungstrøm T, Knudsen H, Nielsen PE. Cellular uptake of adamantyl conjugated peptide nucleic acids. Bioconjugate Chemistry. 1999;10(6):965-972. PMID: 10563765. DOI: 10.1021/bc990053+. pubmed.ncbi.nlm.nih.gov/10563765
- Wanka L, Iqbal K, Schreiner PR. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chemical Reviews. 2013;113(5):3516-3604. PMID: 23432396. DOI: 10.1021/cr100264t. pubmed.ncbi.nlm.nih.gov/23432396
For in-vitro laboratory research only. It is not a human medicine and is not for treatment.